{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:47:56Z","timestamp":1793753276220,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40273-022-01140-y","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T22:03:02Z","timestamp":1656972182000},"page":"751-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review"],"prefix":"10.1007","volume":"40","author":[{"given":"Michal","family":"Witkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Ils\u00f8e","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-7508","authenticated-orcid":false,"given":"Pierre","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"issue":"1","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","volume":"22","author":"CC Lindenmeyer","year":"2018","unstructured":"Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22(1):11\u201321.","journal-title":"Clin Liver Dis"},{"issue":"5","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/jcm10050924","volume":"10","author":"M Flisiak-Jackiewicz","year":"2021","unstructured":"Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD)-new terminology in pediatric patients as a step in good scientific direction? J Clin Med. 2021;10(5):924.","journal-title":"J Clin Med"},{"issue":"3","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","volume":"69","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564\u20138.","journal-title":"Gut"},{"issue":"10027","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513\u201330.","journal-title":"Lancet"},{"issue":"10026","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377\u201396.","journal-title":"Lancet"},{"issue":"1","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"key":"1140_CR7","first-page":"75","volume":"8","author":"BA Banini","year":"2016","unstructured":"Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016;8:75\u201384.","journal-title":"Clin Med Insights Ther."},{"issue":"1","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123\u201333.","journal-title":"Hepatology"},{"issue":"6","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"1","key":"1140_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"9","key":"1140_CR11","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","volume":"90","author":"EK Spengler","year":"2015","unstructured":"Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc. 2015;90(9):1233\u201346.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1140_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol. 2019;71(2):313\u201322.","journal-title":"J Hepatol"},{"issue":"1","key":"1140_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/TP.0000000000002355","volume":"103","author":"PJ Thuluvath","year":"2019","unstructured":"Thuluvath PJ, Hanish S, Savva Y. Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic, or AIH cirrhosis. Transplantation. 2019;103(1):113\u201321.","journal-title":"Transplantation"},{"issue":"5","key":"1140_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577\u201386.","journal-title":"Hepatology"},{"key":"1140_CR15","unstructured":"World Health Organization. WHO guide to identifying the economic consequences of disease and injury. 2009. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/137037\/9789241598293_eng.pdf?sequence=1&isAllowed=y. Accessed 19 Apr 2021."},{"issue":"3","key":"1140_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/1358863X08091738","volume":"13","author":"I Durand-Zaleski","year":"2008","unstructured":"Durand-Zaleski I. Why cost-of-illness studies are important and inform policy. Vasc Med. 2008;13(3):251\u20133.","journal-title":"Vasc Med"},{"key":"1140_CR17","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (editors). Cochrane handbook for systematic reviews of interventions version 6.0. Cochrane. 2019. http:\/\/training.cochrane.org\/handbook. Accessed 11 February 2020.","DOI":"10.1002\/9781119536604"},{"key":"1140_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1140_CR19","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Third edition. Oxford: Oxford University Press; 2005.","edition":"3"},{"issue":"5","key":"1140_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1524-4733.2008.00327.x","volume":"11","author":"L Molinier","year":"2008","unstructured":"Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Souli\u00e9 M, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008;11(5):878\u201385.","journal-title":"Value Health."},{"issue":"9","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/MCG.0000000000001109","volume":"53","author":"ES Aby","year":"2019","unstructured":"Aby ES, Lee E, Saggi SS, Viramontes MR, Grotts JF, Agopian VG, et al. Pretransplant sarcopenia in patients with NASH cirrhosis does not impact rehospitalization or mortality. J Clin Gastroenterol. 2019;53(9):680\u20135.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1140_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","volume":"256","author":"VG Agopian","year":"2012","unstructured":"Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256(4):624\u201333.","journal-title":"Ann Surg"},{"issue":"6","key":"1140_CR23","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1097\/TXD.0000000000000674","volume":"3","author":"AS Barbas","year":"2017","unstructured":"Barbas AS, Goldaracena N, Dib MJ, Al-Adra DP, Aravinthan AD, Lilly LB, et al. Early intervention with live donor liver transplantation reduces resource utilization in NASH: the Toronto experience. Transplant Direct. 2017;3(6):e158.","journal-title":"Transplant Direct."},{"issue":"11","key":"1140_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/lt.25637","volume":"25","author":"MC Morris","year":"2019","unstructured":"Morris MC, Jung AD, Kim Y, Lee TC, Kaiser TE, Thompson JR, et al. Delayed sleeve gastrectomy following liver transplantation: a 5-year experience. Liver Transpl. 2019;25(11):1673\u201381.","journal-title":"Liver Transpl"},{"issue":"7","key":"1140_CR25","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/liv.12770","volume":"35","author":"RS Hoehn","year":"2015","unstructured":"Hoehn RS, Singhal A, Wima K, Sutton JM, Paterno F, Woodle ES, et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. Liver Int. 2015;35(7):1902\u20139.","journal-title":"Liver Int"},{"issue":"3","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","volume":"1","author":"M-M Balp","year":"2019","unstructured":"Balp M-M, Krieger N, Przybysz R, Way N, Cai J, Zappe D, et al. The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study. JHEP Rep. 2019;1(3):154\u201361.","journal-title":"JHEP Rep."},{"issue":"5","key":"1140_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/lt.25443","volume":"25","author":"P Axley","year":"2019","unstructured":"Axley P, Ahmed Z, Arora S, Haas A, Kuo Y-F, Kamath PS, et al. NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States: a population-based study. Liver Transpl. 2019;25(5):695\u2013705.","journal-title":"Liver Transpl"},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.diabres.2017.07.030","volume":"132","author":"JE Carruthers","year":"2017","unstructured":"Carruthers JE, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP. Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. Diabetes Res Clin Pract. 2017;132:102\u20137.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1140_CR29","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cgh.2020.06.064","volume":"19","author":"A Geier","year":"2021","unstructured":"Geier A, Rinella ME, Balp M-M, McKenna SJ, Brass CA, Przybysz R, et al. Real-world burden of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021;19(5):1020\u20139.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1140_CR30","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","volume":"2","author":"J Ohara","year":"2020","unstructured":"Ohara J, Finnegan A, Dhillon D, Ruiz-Casas L, Pedra G, Franks B, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020;2(5):100142.","journal-title":"JHEP Rep."},{"issue":"5","key":"1140_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MCG.0000000000001389","volume":"55","author":"M Reja","year":"2021","unstructured":"Reja M, Patel R, Pioppo L, Tawadros A, Bhurwal A, Marino D, et al. Renal failure is associated with increased mortality and hospital utilization in patients admitted with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2021;55(5):433\u20138.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"1140_CR32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/hepr.13535","volume":"50","author":"RP Tampi","year":"2020","unstructured":"Tampi RP, Wong VW-S, Wong GL-H, Shu SS-T, Chan HL-Y, Fung J, et al. Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: data from Hong Kong. Hepatol Res. 2020;50(9):1024\u201331.","journal-title":"Hepatol Res"},{"issue":"2","key":"1140_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/dc19-1113","volume":"43","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Tampi RP, Racila A, Qiu Y, Burns L, Younossi I, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. Diabetes Care. 2020;43(2):283\u20139.","journal-title":"Diabetes Care"},{"issue":"5","key":"1140_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40273-019-00881-7","volume":"38","author":"P Johansen","year":"2020","unstructured":"Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic literature review and critical appraisal of health economic models used in cost-effectiveness analyses in non-alcoholic steatohepatitis: potential for improvements. Pharmacoeconomics. 2020;38(5):485\u201397.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1140_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jama.2018.1150","volume":"319","author":"I Papanicolas","year":"2018","unstructured":"Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024\u201339.","journal-title":"JAMA"},{"issue":"4","key":"1140_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10198-020-01256-y","volume":"22","author":"A Morgan","year":"2021","unstructured":"Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ. 2021;22(4):505\u201318.","journal-title":"Eur J Health Econ"},{"issue":"6","key":"1140_CR37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/liv.14825","volume":"41","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227\u201342.","journal-title":"Liver Int"},{"issue":"7","key":"1140_CR38","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s12325-019-00960-3","volume":"36","author":"M Povsic","year":"2019","unstructured":"Povsic M, Wong OY, Perry R, Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther. 2019;36(7):1574\u201394.","journal-title":"Adv Ther"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01140-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T23:59:18Z","timestamp":1700783958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01140-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"10 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed video was retrospectively added to this publication.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Novo Nordisk A\/S, S\u00f8borg, Denmark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SIM, PJ and MA are employees of Novo Nordisk A\/S or Novo Nordisk Denmark A\/S, and JF was formerly an employee of Novo Nordisk A\/S. SIM, PJ, MA and JF are also shareholders of Novo Nordisk A\/S. MW and SN are employees of DRG Abacus (Clarivate), who were commissioned to perform this systematic literature review by Novo Nordisk A\/S.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable to this article as no datasets were generated or analysed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable to this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable to this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable to this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable to this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"PJ provided the study concept and design. JF, PA and SN performed the data extraction. All authors contributed to the analysis and interpretation of the data and contributed to the drafting of the paper, critically revised the paper for intellectual content, were involved in the final approval of the version to be published and agreed to be accountable for all aspects of the work. PJ is the overall guarantor.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}